RESPONSE TO NIVOLUMAB AS ≥3rd LINE THERAPY IN PTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA (CHL) AND ITS IMPACT ON QUALITY OF LIFE IN RESPONDERS AND NONRESPONDERS. (12th June 2019) - Lepik, K.; Mikhaylova, N.; Kondakova, E.; Tsvetkova, L.; Zalyalov, Y.; Borzenkova, E.; Moiseev, I.; Baykov, V.; Nikitina, T.; Porfir'eva, N.; Ionova, T.; Afanasyev, B.